DFSG 2025
Industry Symposia
Symposia Information
60 min. symposia
Date: Friday 12 September, 15:30-16:30
Room: Don Giovanni 1 to 3
Chair & Speaker:
Assoc.Prof. Vladimíra Fejfarová, MD., Ph.D.
Speaker:
Prof Dr. José Luis Lázaro-Martínez
Advancing diabetic foot care: Innovative tools and real-world insights
Join us for an enlightening symposium where esteemed medical professionals will present their insights on a newly published article about topical oxygen therapy.
This session will explore how ischemia is a critical predictor of delayed wound healing and the role of oxygen in chronic wounds. You will also learn the impact of using the clinical decision support tool on topical oxygen therapy through real-world clinical examples.
Additionally, you will hear firsthand user experiences with Granulox® and how this product has advanced wound healing, ultimately leading to better patient outcomes.
We look forward to your participation.
Date: Saturday 13 September, 11:30-12:30
Room: Don Giovanni 1 to 3
Co-chairs:
Alberto Piaggesi, MD
Matthew Malone, PhD, FFPM RCPS (Glasg)
Speakers:
Daniel Metcalf, PhD
Dr. Chris Manu, MD
Prof Dr. José Luis Lázaro-Martínez
Introducing a Novel, Nitric Oxide-Generating, Multimodal Wound Dressing: Superior Clinical Outcomes in Diabetic Foot Ulcers
In this symposium, our Co-chairs will outline the need for better healing outcomes in diabetic foot ulcers.
We will introduce a new nitric oxide-generating, multimodal wound dressing supported by a range of bench data highlighting its features which support healing. The superior healing outcomes with this new dressing treatment compared to standard of care in a randomized clinical trial will be demonstrated.
Post-hoc analyses from this RCT will outline the dressing’s potential clinical utility, and we will present the first clinical experiences with this new technology in treating DFUs.
Mini-symposia
Date: Saturday 13 September, 13:30-13:50
Room: Don Giovanni 1 to 3
Presenter:
Marco Meloni, MD, PhD
TLC-NOSF dressings as a first-line local treatment for diabetic foot ulcers (DFUs): a systematic review of clinical evidence
TLC-NOSF (Technology Lipidocolloid-Nano Oligosaccharide Factor) dressings are recommended by numerous national and international guidelines for the management of diabetic foot ulcers (DFUs), yet they are often used as a second-line treatment. This can result in missed opportunities for patients and increased costs for payers.
This study aimed to examine the outcomes of wound healing and related costs when TLC-NOSF dressings are used as a primary treatment for patients with DFUs. A total of 17 studies published between 2017 and 2024 met the eligibility criteria. The analysis included data from 10,191 patients of both sexes and different age groups, with a total of 10,203 wounds (including DFUs, leg ulcers, pressure injuries, and other types of chronic wounds).
The results presented reinforce the current guidelines recommending TLC-NOSF dressings for the treatment of DFUs and support their wider implementation as part of the standard of care.
Date: Sunday 14 September, 12:10-12:30
Room: Don Giovanni 1 to 3
Presenter:
Dr. Mike Griffiths
Driving DFUs into remission with multi-modality TWO2 therapy: Latest clinical evidence & growing payer coverage
This presentation will focus on the latest RCT and Real-World Evidence demonstrating the effectiveness of multimodality cyclically pressurized topical wound oxygen (TWO2) therapy in healing Diabetic Foot Ulcers (DFU).
The science will be explored that demonstrates that upregulation of collagen formation and cross-linking, combined with localized angiogenesis, stimulated by using this therapy, results in far better organized and sustainable tissue formation, resulting in more durable healing with reduced ulcer reoccurrence, hospitalizations, and amputations.
Interested in sponsoring DFSG 2025?
Get contacted by our dedicated sponsorship and
exhibition team to explore your opportunities.